Novo’s First Ph3 Icodec Trial (ONWARDS 1) Posted on CT.gov
A new CT.gov record has been observed for Novo Nordisk’s first Ph3 trial evaluating its QW insulin icodec insulin-naïve T2DM patients (ONWARDS 1). Novo appears to be branding the Ph3 program as “ONWARDS” in an effort to pay homage to the continued development story of insulin. In case you missed it, Lilly recently initiated two Ph2 trials for its QW insulin (LY3209590) in both T1DM and T2DM (previous FENIX insight). Below, FENIX provides an overview of the ONWARDS 1 trial as well as brief thoughts on Novo potentially providing additional clarity during its upcoming Q2 ’20 earnings call on August 6, 2020.